TY - JOUR
T1 - Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat
T2 - Insights from experimental heart failure
AU - Chen, Horng H.
AU - Cataliotti, Alessandro
AU - Burnett, John C.
N1 - Funding Information:
The authors gratefully acknowledge the assistance of Den-ise M. Heublein and Sharon S. Sandberg. This research was supported by grants HL 36634 and HL 07111 from the National Institutes of Health, the Miami Heart Research Institute, the Mayo Foundation, the Bruce and Ruth Rappa-port Program in Vascular Biology, and Bristol Myers Squibb Research Institute. Dr. Chen is the recipient of the General Mills Clinician Investigator Fellowship.
PY - 2001
Y1 - 2001
N2 - Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.
AB - Vasopeptidase (VP) inhibitors are novel molecules that coinhibit neutral endopeptidase 24.11 (NEP), which degrades natriuretic peptides and angiotensin-converting enzyme (ACE). We review the biology of the natriuretic peptide system and a recent study of the role for the natriuretic peptide system in the mechanism of action of omapatrilat (the most clinically advanced VP inhibitor). This study compared the cardiorenal and humoral actions of omapatrilat with those of ACE inhibition. The actions of omapatrilat were further defined in the presence and absence of a natriuretic peptide receptor antagonist. This investigation provided insight into a unique new pharmacologic agent that has beneficial renal actions in experimental mild heart failure that exceed those seen with ACE inhibition alone and that are linked to the natriuretic peptide system.
UR - http://www.scopus.com/inward/record.url?scp=0035656143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035656143&partnerID=8YFLogxK
U2 - 10.1007/s11906-001-0102-y
DO - 10.1007/s11906-001-0102-y
M3 - Review article
C2 - 11716801
AN - SCOPUS:0035656143
SN - 1522-6417
VL - 3
SP - s15-s21
JO - Current Hypertension Reports
JF - Current Hypertension Reports
IS - SUPPL. 2
ER -